Inhalation Sciences

We have now secured a new order for a preclinical DissolvIt® study from a returning customer - a top 10 global pharma in inhaled therapies. Valued at 57,000 EURO, the study is for DissolvIt® and high-precision data in the preclinical phase inhalation.se/investors/pres…

Watch ISAB CEO Manoush Masarrat go behind the headlines in a high-value interview on the company’s Q1 report answering questions from investors.This is the first of a series of Quarterly video interviews - watch it in full here! youtube.com/watch?v=OCxHa2x0… #investors #aerosols

17% revenue increase. Continued improved operating profit. FDA research collaboration progressing on schedule. Publication of first clinical study of PreciseInhale. Our Q1 2024 Report is out now. Access it here! inhalation.se/investors/pres… #aerosol #inhalation #investment

We were delighted to present our predictive tools for developing and assessing generic inhaled pharmaceuticals at the FDA’s GDUFA (Generic Drug User Fee Amendments) webinar on May 20! inhalation.se/investors/pres… #investors #aerosols

Our new purchase order worth 60,000 EURO is with one of the world’s Top 5 generics companies, a returning customer. ISAB CEO: “when a customer of this caliber returns, it reconfirms the unique benefits and capabilities of PreciseInhale” inhalation.se/investors/pres… #investor

Register for our next Webinar on May 21 - and explore our archive! Like 100s of other industry professionals discover expert cases on everything from dissolution testing to IVIVC to formulating biologics as dry powders. Visit here: inhalation.se/webinars/ #inhalation

"With 44% growth from 2022 to 2023, continuing increased market share and significant improvement in our operating profit it's been a productive year packed full of scientific and commercial milestones" - CEO Manoush Massarrat. Read the full Report here: inhalation.se/investors/fina…

We are pleased to be invited to provide a public comments presentation at the FDA’s GDUFA (Generic Drug User Fee Amendments) public workshop on May 20th , 2024, as part of the 'Predictive Tools for Generic Product Development & Assessment' session. inhalation.se/investors/pres…

The positive results of our first-in-human clinical study of PreciseInhale are now published in the European Journal of Pharmaceutical Sciences. Ther study unlocks a new addressable market for Inhalation Sciences of 5 Billion SEK. inhalation.se/investors/pres… #FiTwi #investers

"All time high revenue with 50% growth YoY AND improved profitability” our Q4 / Year End Report is out. Read about an exciting quarter - and year - here inhalation.se/investors/pres… #FiTwi #investors

We’re excited to announce our new partnership with Actarmo Medical. Together, our new end-to-end services offering provides expertise every step of the way through the respiratory drug development chain. Read the full story here: inhalation.se/investors/pres… #inhalation #investor

We are pleased to announce a new product service contract worth 47,000 Euro on ISAB instruments at the facilities of a large European pharma company. The order reaffirms the client’s strong commitment to its continuing use of our products. inhalation.se/investors/pres…

Busy days at #DDL2023 in Edinburgh! Great to see a high level of interest in our technology and our Inhalation Research Services! Meet us at Stand 207! inhalation.se #inhalationT #preclinical #aerosol #invitro #invivo #Respiratory

It's been a positive, intensive Quarter for ISAB - read our Q3 Interim Report here. inhalation.se/investors/pres… #investor #finanstwitter #fitwi #inhalation

Pleased to announce our 3rd major order in a month, this one worth 100,000 Euro for an IRS project for a prominent European pharma co, CEO Manoush Masarrat: “cnce again we see a growing demand for advanced in vitro testing systems” inhalation.se/investors/pres… #finanstwitter

We have received a new purchase order worth 276,450 Euro (3.2 MSEK) from a returning customer. CEO Manoush Masarrat “it's a great validation when a customer returns we are grateful for their continued confidence in our products" inhalation.se/investors/pres… #inhalation #finanstwitter

We are pleased to announce a new order valued at 54,700 Euro built on a collaboration with a trusted partner. CEO Manoush Masarrat: “We're happy to enable and drive forward premium partnerships and research solutions like this one” inhalation.se/investors/pres… #finanstwitter

Join our CEO Manoush Masarrat for a 2-minute pitch and 20-minute analyst Q&A at Redeye Life Science Day! inhalation.se/investors/pres… #finanstwitter #inhalation #aerosols #inhaledpharmaceuticals #investering #preclinicalresearch #drugdevelopment

The approval of an extension on a vital patent  will  strengthen ISAB's IP postilion in the US, a crucial market for the company. ISAB CEO Manoush Masarrat, "this will create even stronger exclusivity for our platform and products" inhalation.se/investors/pres… #aerosols #inhalation

We're thrilled to announce a new Inhalation Research Services project, worth 189,900 EURO, with a returning customer - one of the world’s top five generic pharma’ manufacturers. inhalation.se/investors/pres… #inhalation #aerosols #investment